Ubs Group Ag Biogen Inc. Call Options Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	SELL	$190.52 - $236.72 $8.5 Million - $10.6 Million	-44,600 Reduced 29.42%	107,000 $24.8 Million
Q1 2024 May 13, 2024	SELL	$212.02 - $267.71 $11.8 Million - $14.9 Million	-55,800 Reduced 26.9%	151,600 $32.7 Million
Q4 2023 Feb 09, 2024	BUY	$222.59 - $267.94 $3.69 Million - $4.45 Million	16,600 Added 8.7%	207,400 $53.7 Million
Q3 2023 Nov 09, 2023	BUY	$253.3 - $285.89 $28.6 Million - $32.3 Million	112,900 Added 144.93%	190,800 $49 Million
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $1.79 Million - $2.07 Million	6,500 Added 9.1%	77,900 $22.2 Million
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $6.9 Million - $7.86 Million	26,900 Added 60.45%	71,400 $19.9 Million
Q4 2022 Feb 08, 2023	BUY	$252.44 - $306.72 $4.35 Million - $5.28 Million	17,230 Added 63.18%	44,500 $12.3 Million
Q3 2022 Nov 10, 2022	BUY	$194.69 - $268.46 $13,628 - $18,792	70 Added 0.26%	27,270 $7.28 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $9.46 Million - $11.9 Million	-48,800 Reduced 64.21%	27,200 $5.73 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $8.35 Million - $10.7 Million	-37,298 Reduced 32.92%	76,000 $18.2 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $2.97 Million - $3.88 Million	-10,500 Reduced 8.48%	113,298 $32.1 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $2.19 Million - $3.5 Million	8,440 Added 7.32%	123,798 $42.9 Million
Q1 2021 May 12, 2021	BUY	$242.95 - $284.63 $14.5 Million - $17 Million	59,658 Added 107.11%	115,358 $32.3 Million
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $5.36 Million - $8.07 Million	22,700 Added 68.79%	55,700 $13.6 Million
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $794,310 - $917,129	-3,000 Reduced 8.33%	33,000 $9.36 Million
Q2 2020 Jul 31, 2020	SELL	$258.66 - $342.55 $19.8 Million - $26.2 Million	-76,500 Reduced 68.0%	36,000 $9.63 Million
Q1 2020 May 01, 2020	SELL	$268.85 - $341.04 $8.6 Million - $10.9 Million	-32,000 Reduced 22.15%	112,500 $35.6 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $31.7 Million - $43.9 Million	144,275 Added 64122.22%	144,500 $42.9 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $3.78 Million - $4.24 Million	-17,375 Reduced 98.72%	225 $52,000
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $5.39 Million - $5.95 Million	-24,600 Reduced 58.29%	17,600 $4.12 Million
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $25.7 Million - $40.3 Million	-118,800 Reduced 73.79%	42,200 $9.98 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $44.4 Million - $56.3 Million	159,500 Added 10633.33%	161,000 $48.4 Million
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $528,318 - $690,894	-1,800 Reduced 54.55%	1,500 $530,000
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $3.01 Million - $3.59 Million	-11,700 Reduced 78.0%	3,300 $958,000
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $1.3 Million - $1.84 Million	5,000 Added 50.0%	15,000 $4.11 Million
Q4 2017 Feb 14, 2018	SELL	$307.64 - $344.58 $3.63 Million - $4.07 Million	-11,800 Reduced 54.13%	10,000 $3.19 Million
Q3 2017 Nov 14, 2017	SELL	$281.15 - $329.69 $15.4 Million - $18 Million	-54,600 Reduced 71.47%	21,800 $6.83 Million
Q1 2017 Nov 14, 2017	BUY	N/A	76,400	76,400 $20.9 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

Vanguard Group Inc Valley Forge, PA

16.6M
Shares

$2.88 Billion
0.08% of portfolio
Primecap Management CO Pasadena, CA

16.3M
Shares

$2.84 Billion
2.78% of portfolio
Black Rock Inc. New York, NY

14.5M
Shares

$2.53 Billion
0.08% of portfolio
State Street Corp Boston, MA

7.1M
Shares

$1.23 Billion
0.07% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

5.68M
Shares

$987 Million
0.83% of portfolio

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account